been evaluated to achieve better platelet inhibition, but the standard approach has not been established for the management of high platelet reactivity (HPR) on DAPT. This is partly because an event rate of atherothrombosis after PCI is low, and HPR usually yields a low positive predictive value. Conversely, the lack of HPR yields a high negative predictive value for thrombosis, and is even associated with increased bleeding complications.
9 10 Screening for reduced platelet aggregation on DAPT is of particular interest to anaesthetists and surgeons because it can be helpful in gauging timing of an invasive procedure, 11 12 or an indication for platelet transfusion. 13 -15 The assessment of platelet function after platelet transfusion is also an important consideration because transfused platelets can be affected by circulating platelet inhibitors.
In the current issue of BJA, Hansson and colleagues 16 report differences in the functional platelet recovery after in vitro addition of allogeneic platelets in whole blood samples from patients on ASA, ASA plus clopidogrel, or ASA plus ticagrelor. Platelet aggregation was evaluated in hirudin-anticoagulated whole blood using multi-electrode aggregometry (MEA) (Multiplate w , Munich, Germany). Antiplatelet effects of ASA and P2Y 12 inhibitors were presumably maximal when the specimens were collected within 2 h of the last drug ingestion (Table 2) . 17 -19 This experiment mirrors the 'worst-case scenario' where an emergency coronary bypass grafting surgery (CABG) is being requested after failed PCI. Uninterrupted DAPT has been associated with haemorrhagic complications and increased transfusion requirements after CABG. 20 21 There were three principal findings in this study: (i) ADP-induced aggregation in the presence of clopidogrel or ticagrelor was minimally improved by platelet supplementation, (ii) antiplatelet effect of ASA was readily reversible with platelet supplementation, and (iii) P2Y 12 inhibitors interfere with the platelet recruitment process via thromboxane and thrombin receptors, but the reduced responsiveness to non-ADP agonists was improved by platelet supplementation.
First, ADP-induced platelet aggregation (AU×min) showed a statistically significant improvement after adding moderate and high platelet doses in both ASA plus clopidogrel or ASA plus ticagrelor samples. Mean peak values (21 and 16 AU×min, respectively) remained far below the normal range of aggregablity for ADP tests (43 -100 AU×min). A preoperative cut-off value of 31 AU×min has been associated with increased postoperative bleeding (.800 ml in 12 h) after cardiac surgery. 22 It is thus speculated that more than 2 -5 units of apheresis platelets would be required to restore ADP-induced platelet aggregation when active antiplatelet agents are high in circulation.
As discussed by the authors, Vilahur and colleagues 23 previously demonstrated in vitro that decreased platelet aggregation after 3 days of ASA plus clopidogrel was restored to .80% of normal after adding fresh platelet-rich plasma (PRP) equivalent to 2-3 units of apheresis platelets. It is notable that blood samples used for PRP supplementation were drawn at 72 h from the loading dose (ASA 325 mg, and clopidogrel 300 or 600 mg) and 24 h from the last dose. 23 Near-complete reversal of platelet function in their study is thus partly attributable to the lack of active antiplatelet agents in the subjects' blood. Time dependence of functional platelet recovery was also demonstrated for prasugrel. In
Zafar and colleagues' study, 24 platelet aggregation by LTA and VerifyNow-P2Y 12 assay recovered only slightly when fresh PRP (equivalent to 3-4 apheresis units) was used to supplement the subjects' blood obtained 2 h after a single loading dose (60 mg) of prasugrel plus ASA. Hansson and colleagues 16 found that platelet supplementation was less effective in blood affected by ASA plus ticagrelor compared with ASA plus clopidogrel within 2 h from the last dose. However, adding a wait time of 6-24 h would allow natural recovery of platelets from ticagrelor, 25 and improve the efficacy of transfused platelets based on its pharmacokinetics (Table 2) . Another potential confounding element in platelet transfusion is the quality of platelets. In this regard, Prü ller and colleagues 26 demonstrated that transfusion of 3-day-old apheresis platelets (2 units) in subjects who received a 3-day course of ASA plus clopidogrel did not immediately improve platelet aggregation (LTA) induced by arachidonic acid or ADP, but they moderately improved aggregation (31 -38%) in 24 h. The platelet apheresis devices used by Prü ller's group 26 and Hansson's group 16 were the same, and therefore it is speculated that clinical efficacy of stored platelet transfusion could be overestimated by the experimental use of fresh platelet concentrates (,6 h of collection). In addition to ADP-induced aggregation, Hansson and colleagues 16 reported arachidonic acid responses to incremental doses of platelets. ASA-induced platelet inhibition was readily reversible with the lowest platelet dose, but inhibitory effects of ASA plus clopidogrel or ASA plus ticagrelor required mediumhigh platelet doses to approach normal aggregation. As mentioned above, excellent platelet responsiveness to arachidonic acid underlies the quality of fresh platelet concentrate used by Hansson and colleagues, 16 but stored platelets could be less efficacious than fresh ones. 26 The safety of preoperative ASA was assessed in the prospective study of non-cardiac surgical patients with cardiovascular risks. ASA (75 mg qd; n¼145) or placebo (n¼146) was randomly assigned to patients 10 days before the scheduled surgery. Approximately 70 and 30% of all patients were chronically on ASA and clopidogrel. There were no differences between continuation and interruption of ASA in terms of major thrombotic or bleeding events within 30 days of surgery. It is recommended to continue ASA in preoperative patients with cardiovascular risks because the antithrombotic benefit of ASA is considerably greater than the risk of bleeding. 27 Monotherapy with ASA does not increase the risk of haematoma in patients who undergo regional anaesthesia (e.g. spinal block). 28 29 Finally, Hansson and colleagues 16 observed that platelets from patients on DAPT yielded 25% lower aggregation in response to thrombin receptor agonist peptide (TRAP). Jakubowski and colleagues 30 had previously shown that mean platelet aggregation (LTA) induced by TRAP was reduced by 27% with prasugrel plus ASA, and by 15% with clopidogrel plus ASA. Cross-interactions among different platelet agonists and receptors are important in the formation of haemostatic plugs or pathological thrombus (Fig. 1) . 31 In this regard, Hosokawa and colleagues 32 33 recently developed a microchip-based flow-chamber system that enables evaluation of platelet thrombus formation influenced by ASA, P2Y 12 inhibitors, or their combination under physiological shear rates (1000 -2000 s 21 ). Perfused platelets in hirudin-anticoagulated whole blood are activated by shear over the collagen-coated capillary, and thrombus (i.e. platelet aggregates) is subsequently formed after the endogenous release of thromboxane A 2 and ADP from adherent platelets (Fig. 1) . This new monitoring approach appears to yield reasonable correlations with the MEA-collagen test for ASA and the MEA-ADP test for DAPT. 33 High negative predictive value (.90%), and low positive predictive value (,20%) for atherothrombotic events have been demonstrated with many platelet assays.
2 4 5 Similarly, a MEA-ADP test cut-off of 31 AU×min was found to have 92% negative predictive value, but 29% positive predictive value for bleeding after cardiac surgery. 22 These findings suggest that most patients do not develop thrombotic complications despite HPR on DAPT, and most patients with low platelet aggregability do not suffer from bleeding complications. Currently available platelet function tests are limited to the assessment of platelet aggregation and adhesion, and platelet-mediated haemostatic activities, including microparticle release and procoagulant reactions, cannot be ascertained. 34 Other bleeding risk factors besides platelet function should also be considered in the perioperative management of haemostasis in cardiovascular patients. Corrections of hypofibrinogenaemia and reduced vitamin K-dependent clotting factors using fibrinogen concentrate and prothrombin complex concentrate are particularly important in the presence of thrombocytopenia, platelet dysfunction, or both. The combination of global coagulation tests (thromboelastometry or thromboelastography) and MEA is one exemplary strategy to manage the use of factor concentrate plasma and platelets rationally.
13 -15 35 36 Recombinant activated factor VII 37 and antifibrinolytic therapy 38 may be also useful for bleeding associated with platelet inhibitors. Clinical management for the patients with cardiovascular risks has been rapidly evolving with the introduction of novel antithrombotic and antiplatelet agents.
1 A wide variety of platelet function tests with different techniques and end points is commercially available, but they are not routinely utilized to guide perioperative antiplatelet therapy at most medical institutions. This is largely attributable to the lack of standardization of platelet testing, and to the weak positive predictive value for atherothrombosis and bleeding. Platelets are empirically transfused, 39 and their efficacy is guessed from an increase in platelet count. Individualized platelet transfusion is more desirable in terms of reducing the overall cost and the risk of allergic reaction, pathogen transmission, and immunomodulation associated with allogeneic platelets. 35 The observations by Hansson and colleagues 16 and results of other similar studies 23 24 26 clearly demonstrate that the efficacy of platelet transfusion is strongly affected by the type of platelets (fresh vs stored), volume of transfusion, and circulating antiplatelet agents (active metabolites). Although still preliminary, these data collectively point to our future goal of individualized platelet transfusion therapy, in which optimal indications and doses of platelet transfusion can be selected in a timely fashion.
